苹果官网

新一代G-Sync的诞生与bfgd的开启：没有人能阻止英威达_我的网站

A |     Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。在CES 2019年主旨演讲中，黄仁勋大部分时间都离开了赛场。因此，2019年的因维达CES展自然会包括新产品和新技术。在特别的游戏演示室里，我们看到了Geforce RTX 2060笔记本，一款全新的G-Sync显示产品，以及一款65英寸的Omen Eperium 65 bfgd显示屏，即将出售。G-SYNC重新进化G-SYNC和Geforce图形卡无疑是完美的匹配。在新闻发布会上，英伟达将G-Sync细分为三个级别，最低级别为无G-Sync，其次为G-Sync兼容，最高级别为G-Sync终极。

B | G-Sync兼容并不意味着它必须为G-Sync技术而构建，但在Nvidia的实际测试中，它仍然能与G-Sync显示出良好的兼容性，这意味着它可以在不付出太多成本的情况下实现与G-Sync显示类似的性能。在超过400个可变刷新率监视器的实际测试中，只有12个监视器符合G-SYNC兼容标准，NVIDA慷慨地给出了推荐购买列表供玩家参考。顾名思义，G-Sync Ultimate是下一段时间内G-Sync的最高标准。它将代表所有高端显示技术的集合，例如需要支持HDR 10、高可变刷新率、超低响应时间、配备G-Sync芯片等。英维达还展示了一些尴尬的只支持自由同步显示在游戏过程中，如闪光屏幕，绘画撕裂等。似乎在N卡前面的自由同步的强制打开没有太多好的水果吃。

C | 当然，英伟达对朋友的支持也不缺，比如35英寸的罗格-斯威夫特PG35VQ将被出售。它不仅支持G-SYNC 3440 x 1440，而且刷新率为200赫兹。价格似乎不便宜。

D | 更便宜的是即将推出的bfgd 65英寸显示器omen eperium 65，最大4K 144Hz加上G同步和屏蔽功能。毫无疑问，惠普甚至减轻了显示器的重量，使其在正式量产之前更容易搬运和挂在墙上。

E | 同时，这种显示器在国外的价格接近5000美元，足以让我们买一台高端4K电视机。

F | Geforce RTX 2060笔记本到Geforce RTX 2060图形卡以及Geforce RTX 2080、RTX 2070笔记本也在现场展出。在Geforce RTX 2060的测试中，我们发现Geforce RTX 2060的性能与Geforce GTX 1070 Ti相当，但DLSS和RTX使其更具吸引力。

G | 现场演示也是如此。通过游戏优化和DLSS合作，Geforce RTX2060可以在保证高质量的前提下轻松实现光线跟踪效果和高帧数，这也使得视频卡本身具有成本效益。RTX笔记本可能是游戏笔记本玩家最容易达到高潮的产品。现场显示笔记本电脑包括Microstar GS65、Lenovo Y740、Razer Blade 15、Alienware M15、Rog Zephrus S GX531、Acer Preditor Triton均使用Geforce RTX 2080 Max-Q图形卡，而HP Omen、Giga Aero 15和Microstar GS75则使用Geforce RTX 2070 Max-Q玩游戏。演示、流利、管理得当就足够了。关键是Geforce RTX系列图形卡笔记本电脑也更容易获得完整的游戏体验。毕竟，你不需要额外的G-SYNC显示器，笔记本电脑制造商也不会通过成本控制夸大他们的价格。可以肯定的是，2019年的钱包生活注定是艰难的。无论是Geforce RTX笔记本电脑、G-Sync显示器还是台式电脑，都有很多花钱的理由，而且这些产品中的许多很快将在第一季度上市销售。似乎如果没有2019年的Computex，今年的PC升级预算将耗尽。

Current article:http://ytp6.senbatuqiuzhuanlanrilao.sbs/uex3/20260826/312.html

Published on:00:00:00